Alumis (ALMS) Completes Merger with ACELYRIN

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/17/2026

1. VRNS
2. CRWV
3. JBHT
4. TSLA
5. SCHW
6. GPRK
7. TRV
8. TFC
9. TECHM:IN
10. NVDA

Go back to Alumis (ALMS) Completes Merger with ACELYRIN

Alumis Completes Merger with ACELYRIN

May 21, 2025 9:10 AM EDT

SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that it has completed its merger with ACELYRIN, Inc.

Each ACELYRIN stockholder will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned. ACELYRIN common stock has ceased trading and will no longer be listed on the NASDAQ Global Select Market.

We are excited to complete our merger and move forward with a significantly strengthened balance sheet to support Alumis differentiated late-stage... More